oxazoles has been researched along with Disease Exacerbation in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bachelot, T; Bailleux, C; Darlix, A; Jacot, W | 1 |
| Abramson, V; An, X; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Cameron, D; Carey, L; Chien, AJ; Conlin, A; Curigliano, G; DiGiovanna, MP; Gelmon, K; Hamilton, E; Hurvitz, S; Lin, NU; Loi, S; Loibl, S; Mayor, J; McGoldrick, S; Mueller, V; Murthy, RK; O'Regan, R; Okines, A; Oliveira, M; Paplomata, E; Wardley, A; Winer, EP; Zelnak, A | 1 |
| Cadegiani, F; Goren, A; Lin, EM; Wambier, CG | 1 |
| Cosentino, F; Grobbee, DE; Lincoff, AM; Mellbin, L; Morici, N; Nozza, A; Perrone Filardi, P; Ponticelli, C; Savonitto, S; Schrieks, IC; Schwartz, GG; Stähli, BE; Tardif, JC | 1 |
| Ha, H; Jin, WJ; Kim, B; Kim, HH; Lee, JH; Lee, ZH | 1 |
| Bogdán, D; Borbély, É; Botz, B; Csepregi, JZ; Helyes, Z; Horváth, Á; Juhász, T; Keeble, J; Kemény, Á; Mátyus, P; Menghis, A; Mócsai, A; Pintér, E; Tékus, V; Zákány, R | 1 |
| Fujiki, H; Suganuma, M | 1 |
| Baader, M; Breitschopf, K; Falk, E; Gerl, M; Kramer, W; Linz, W; Rütten, H; Schäfer, HL; Wohlfart, P | 1 |
| Doi, K; Fukushima, S; Mitsuhashi, M; Moku, M; Morimura, K; Salim, EI; Shen, J; Wanibuchi, H; Wei, M | 1 |
| Fukushima, S; Hakoi, K; Moku, M; Morimura, K; Salim, EI; Shen, J; Wanibuchi, H; Wei, M | 1 |
| Bai, R; Dettin, LE; Glazer, RI; Kopelovich, L; Kopleovich, L; Kozikowski, AP; Russell, RG; Wei, ZL; Yin, Y | 1 |
| Belder, R; Chen, S; Cheng, PT; Devasthale, P; Egan, D; Farrelly, D; French, M; Gu, L; Hariharan, N; Harrity, T; Janovitz, E; Kunselman, L; Peters, A; Ponticiello, R; Staal, A; Swartz, J; Taylor, S; Tozzo, E; Welzel, G; Whaley, J; Zebo, R | 1 |
2 review(s) available for oxazoles and Disease Exacerbation
| Article | Year |
|---|---|
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2021 |
Carcinogenic aspects of protein phosphatase 1 and 2A inhibitors.
Topics: Animals; Carcinogens; Disease Progression; Enzyme Inhibitors; Humans; Marine Toxins; Mice; Models, Molecular; Neoplasms; Neoplasms, Experimental; Okadaic Acid; Oxazoles; Protein Phosphatase 1; Protein Phosphatase 2; Rats; Skin Neoplasms; Stomach Neoplasms; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha | 2009 |
2 trial(s) available for oxazoles and Disease Exacerbation
| Article | Year |
|---|---|
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Double-Blind Method; Female; Humans; Middle Aged; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult | 2020 |
Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Analysis of Variance; Biomarkers; Cause of Death; Comorbidity; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Oxazoles; Patient Discharge; Percutaneous Coronary Intervention; Peroxisome Proliferator-Activated Receptors; Predictive Value of Tests; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Thiophenes | 2017 |
8 other study(ies) available for oxazoles and Disease Exacerbation
| Article | Year |
|---|---|
Potential risk for developing severe COVID-19 disease among anabolic steroid users.
Topics: Adult; Anabolic Agents; Androgen Antagonists; COVID-19 Drug Treatment; Disease Progression; Humans; Male; Oxandrolone; Oxazoles; Performance-Enhancing Substances; SARS-CoV-2; Severity of Illness Index; Thiohydantoins | 2021 |
JN-2, a C-X-C motif chemokine receptor 3 antagonist, ameliorates arthritis progression in an animal model.
Topics: Animals; Arthritis, Rheumatoid; Cell Movement; Chemokine CXCL10; Chemokines, CXC; Cytokines; Disease Models, Animal; Disease Progression; Male; Mice; Oxazoles; Transcription Factor RelA | 2018 |
Analgesic and Anti-Inflammatory Effects of the Novel Semicarbazide-Sensitive Amine-Oxidase Inhibitor SzV-1287 in Chronic Arthritis Models of the Mouse.
Topics: Amine Oxidase (Copper-Containing); Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents; Arthritis; Cells, Cultured; Chronic Disease; Disease Models, Animal; Disease Progression; Freund's Adjuvant; Humans; Hydrazines; Joints; Mice; Mice, Inbred Strains; Mice, Transgenic; Oxazoles; Oximes | 2017 |
The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzoates; Biomarkers; Cardiotonic Agents; Cell Line; Disease Progression; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Male; Molecular Structure; Nitric Oxide Synthase Type III; Oxazoles; PPAR alpha; Ramipril; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Survival Rate; Thiazolidinediones | 2009 |
Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1, 2-dimethylhydrazine-induced rat colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Benzenesulfonates; Bromodeoxyuridine; Carcinogens; Cell Division; Colon; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; Isoenzymes; Male; Oxazoles; Precancerous Conditions; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred F344 | 2003 |
JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Adenoma; Animals; Benzenesulfonates; Biomarkers, Tumor; Carcinogens; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; Gene Expression Profiling; Isoenzymes; Male; Oligonucleotide Array Sequence Analysis; Oxazoles; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred F344 | 2005 |
Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Carcinoma, Adenosquamous; Carcinoma, Ductal; Carcinoma, Squamous Cell; Cell Differentiation; Disease Progression; Female; Gene Expression Profiling; Mammary Neoplasms, Experimental; Mice; Oxazoles; PPAR delta; PPAR gamma; Thiazoles; Tyrosine | 2005 |
The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice.
Topics: Animals; Body Weight; C-Peptide; Diabetes Mellitus, Experimental; Disease Progression; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Glycated Hemoglobin; Glycine; Hypoglycemic Agents; Insulin; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Oxazoles; Pancreas; PPAR alpha; PPAR gamma; Triglycerides | 2007 |